Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) and Sanuwave Health (NASDAQ:SNWV – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Profitability
This table compares Intelligent Bio Solutions and Sanuwave Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -294.88% | -175.35% | -91.25% |
| Sanuwave Health | 32.38% | 1,728.10% | 39.04% |
Analyst Ratings
This is a summary of current recommendations for Intelligent Bio Solutions and Sanuwave Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 1 | 1 | 0 | 0 | 1.50 |
| Sanuwave Health | 2 | 0 | 1 | 0 | 1.67 |
Sanuwave Health has a consensus target price of $47.00, suggesting a potential upside of 820.13%. Given Sanuwave Health’s stronger consensus rating and higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Intelligent Bio Solutions.
Earnings and Valuation
This table compares Intelligent Bio Solutions and Sanuwave Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $4.22 million | 1.34 | -$12.43 million | ($9.02) | -0.19 |
| Sanuwave Health | $44.05 million | 1.00 | $11.81 million | $0.24 | 21.28 |
Sanuwave Health has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Intelligent Bio Solutions has a beta of 4.31, indicating that its stock price is 331% more volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Insider and Institutional Ownership
33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 14.4% of Sanuwave Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Sanuwave Health beats Intelligent Bio Solutions on 12 of the 14 factors compared between the two stocks.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
About Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
